Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 7,313,582 shares of common stock at $81.00 per share, aiming to raise approximately $625 million before expenses [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering is expected to close on March 12, 2026, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,157,407 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Regulatory Information - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on January 30, 2026 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [3]. Group 4: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].

Core Viewpoint - Dianthus Therapeutics, Inc. is actively participating in the 8th Annual Evercore Healthcare Conference, indicating its commitment to engaging with investors and showcasing its developments in the biotechnology sector focused on severe autoimmune diseases [1]. Company Overview - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York City and Waltham, Massachusetts, dedicated to developing next-generation therapies for severe autoimmune diseases [3]. - The company is led by an experienced team of biotech and pharmaceutical executives aiming to deliver transformative medicines for patients suffering from severe autoimmune and inflammatory diseases [3]. Event Participation - CEO Marino Garcia will participate in a fireside chat on December 2, 2025, at 2:35 p.m. ET, and will also host one-on-one meetings with investors during the conference [1]. - A webcast of the presentation will be available under the "News and Events" section of the Dianthus Therapeutics website [2].